In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335 | Zendy

Lisette Lagacé | Zendy; Peter W. White | Zendy; Christiane Bousquet | Zendy; Nathalie Dansereau | Zendy; Florence Dô | Zendy; Montse LlinàsBrunet | Zendy; Martin Marquis | Zendy; Marie-Josée Massariol | Zendy; Roger Maurice | Zendy; Catherine Spickler | Zendy; Diane Thibeault | Zendy; Ibtissem Triki | Zendy; Songping Zhao | Zendy; George Kukolj | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335

Author(s) -

Lisette Lagacé,

Peter W. White,

Christiane Bousquet,

Nathalie Dansereau,

Florence Dô,

Montse LlinàsBrunet,

Martin Marquis,

Marie-Josée Massariol,

Roger Maurice,

Catherine Spickler,

Diane Thibeault,

Ibtissem Triki,

Songping Zhao,

George Kukolj

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.05166-11

Subject(s) - ns3 , virology , genotype , in vitro , protease , protease inhibitor (pharmacology) , biology , replicon , hepatitis c virus , virus , genetics , enzyme , gene , biochemistry , plasmid , viral load , antiretroviral therapy

Thein vitro resistance profile of BI 201335 was evaluated through selection and characterization of variants in genotype 1a (GT 1a) and genotype 1b (GT 1b) replicons. NS3 R155K and D168V were the most frequently observed resistant variants. Phenotypic characterization of the mutants revealed shifts in sensitivity specific to BI 201335 that did not alter susceptibility to alpha interferon. In contrast to macrocyclic and covalent protease inhibitors, changes at V36, T54, F43, and Q80 did not confer resistance to BI 201335.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research